Latest Product Development News

Bio-Gene Technology Limited has been awarded two significant grants totaling A$3 million by the US Department of Defense, validating its innovative insecticide technologies Flavocide® and Qcide®. The company is advancing regulatory filings and scaling production to target both military and civilian markets.

First Graphene Limited reported a successful A$2.4 million capital raise alongside promising progress in its PureGRAPH-CEM product trials in the UK and South Africa, while securing key patents and expanding distribution across Asia and South America.

Rent.com.au Limited reported a net cash outflow of $497k in Q3 FY25 but secured a $1.7 million capital injection through a fully-underwritten entitlement issue to support ongoing operations.

Deterra Royalties Limited reported a 4% increase in portfolio revenue to AUD 61.9 million for the March 2025 quarter, driven by robust iron ore royalties and record gold margins. The company also marked a major milestone with the Final Investment Decision and full funding secured for Phase 1 of the Thacker Pass Lithium Project, targeting production in 2027.

Orbital Corporation Ltd reported a positive operating cash flow of $0.7 million for Q1 2025, supported by a solid order book and ongoing development of a new larger capacity engine prototype.

My Rewards International has completed its acquisition of Fly Wallet and strengthened its financial position with a $15 million put option facility, while working to lift its ASX trading suspension.

Uscom Limited reported a 14% rise in Q3 customer receipts to $0.73 million, even as cash reserves dropped 38% to $1.34 million, reflecting increased operating costs and global market pressures.

Streamplay Studio Limited reported a remarkable 827% increase in customer receipts for Q3 2025, driven by the full integration of Noodlecake Studios. With a robust cash balance of A$7.7 million and no debt, the company is well-positioned to accelerate growth across cloud gaming, game publishing, and emerging markets.

LTR Pharma reports strong Q1 2025 progress with FDA pre-IND meeting success, scientific acclaim for SPONTAN’s rapid absorption, and strategic launch of ROXUS to fast-track US market entry.

Nuchev Limited reported a remarkable 215% increase in quarterly revenue, driven by the strategic launch of Oli6® in Vietnam and the acquisition of bWellness, signaling robust expansion across key Asia-Pacific markets.

Lumos Diagnostics reported a 21% quarter-on-quarter revenue increase in Q3 FY25, driven by strong product sales and expanded development agreements. The company also secured Medicare coverage in key US regions and advanced its pivotal FebriDx CLIA waiver study with FDA submission expected by year-end.

RMA Global Limited reported a robust Q3 FY25, achieving a 21% revenue increase to $5.5 million and marking its third consecutive quarter of positive operating cash flow, driven by US market expansion and the strategic acquisition of Curated Social.